In the present study, we have employed a unique
breast cancer cell line (Met-1, which was derived from a high metastatic potential
tumor in transgenic mice expressing polyomavirus middle T oncogene) to study the role of CD44 variant
isoform(s) in the regulation of metastatic
breast tumor cell behavior. The results of
reverse transcriptase-polymerase chain reaction, Southern blot,
nucleotide sequencing, immunoprecipitation, and immunoblot analyses indicated that these cells express a major CD44
isoform (molecular weight approximately 260 kDa) containing a v3,8-10 exon insertion (designated as CD44v3,8-10). In addition, we have determined that
CD44v3,8-10 binds specifically to the
cytoskeletal proteins such as
ankyrin. Biochemical analyses, using competition binding assays and a synthetic
peptide identical to NGGNGTVEDRKPSEL (a sequence located between aa480 and aa494 of CD44v3,8-10) indicate that this 15-amino
acid peptide binds specifically to the cytoskeletal
protein ankyrin (but not to
fodrin or
spectrin). This
peptide competes effectively for
ankyrin binding to
CD44v3,8-10. Therefore, we believe that the sequence 480NGGNGTVEDRKPSE494L, located at the cytoplasmic domain of
CD44v3,8-10, is required for the
ankyrin binding. We have also detected that CD44v3,8-10-containing Met-1 cells are capable of forming membrane spikes or "invadopodia" structures and undergo active migration processes. Treatments of Met-1 cells with certain agents including anti-CD44v3 antibody,
cytochalasin D (a microfilament inhibitor), and
W-7 (a
calmodulin antagonist), but not
colchicine (a microtubule disrupting agent) effectively inhibit "invadopodia" formation and subsequent
tumor cell migration. Further analyses using zymography assays and double immunofluorescence staining indicated that
CD44v3,8-10 is closely associated with the active form of
matrix metalloproteinase, MMP-9, in a complex within "invadopodia" structures. These findings suggest that
CD44v3,8-10 plays an important role in linking
ankyrin to the membrane-associated
actomyosin contractile system required for "invadopodia" formation (coupled with matrix degradation activities) and
tumor cell migration during
breast cancer progression.